Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients.

MLA

Y. H. Park, et al. “Trastuzumab Treatment Improves Brain Metastasis Outcomes through Control and Durable Prolongation of Systemic Extracranial Disease in HER2-Overexpressing Breast Cancer Patients.” British Journal of Cancer, vol. 100, no. 6, Mar. 2009, pp. 894–900. EBSCOhost, https://doi.org/10.1038/sj.bjc.6604941.

APA

Y. H. Park, M. J. Park, S. H. Ji, S. Y. Yi, D. H. Lim, D. H. Nam, J.-I. Lee, W. Park, D. H. Choi, S. J. Huh, J. S. Ahn, W. K. Kang, K. Park, Y.-H. Im, Park, Y. H., Park, M. J., Ji, S. H., Yi, S. Y., Lim, D. H., & Nam, D. H. (2009). Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. British Journal of Cancer, 100(6), 894–900. https://doi.org/10.1038/sj.bjc.6604941

Chicago

Y. H. Park, M. J. Park, S. H. Ji, S. Y. Yi, D. H. Lim, D. H. Nam, J.-I. Lee, et al. 2009. “Trastuzumab Treatment Improves Brain Metastasis Outcomes through Control and Durable Prolongation of Systemic Extracranial Disease in HER2-Overexpressing Breast Cancer Patients.” British Journal of Cancer 100 (6): 894–900. doi:10.1038/sj.bjc.6604941.